Drugs / BAY2395840
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05406219 | May → Aug 2023 | diabetic polyneuropathy, impaired renal function disease | Bayer | Withdrawn | No outcome recorded |
| Phase 1 | NCT05563454 | Oct 2022 → Feb 2023 | diabetic polyneuropathy | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT05517746 | Dec 2019 → Dec 2020 | endometriosis | Bayer | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT05219812 | Feb → Nov 2022 | diabetes mellitus, diabetic polyneuropathy, neuropathy, painful | Bayer | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY2395840 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05517746 ↗ |
| Action | Inhibit | “BAY 2395840 works by blocking a receptor called the bradykinin B1 receptor, or B1R.” NCT05219812 ↗ |
| Route | Oral | “All participants in this study will take BAY 2395840 and a placebo as tablets by mouth.” NCT05219812 ↗ |